GlassScriptPhysician profile
James R Bavis
NPI 1407880198
$7,303.81
in general payments reported to CMS, 2019-2025
32 companies · $2,980 in 2025
The $2,980 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $65.85 · 2021: $394 · 2022: $770 · 2023: $1,176 · 2024: $1,760 · 2025: $2,980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,715 · Education: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,714.97 |
| Education | $201.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,303.80 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Teva Pharmaceuticals USA, INC. | $984.64 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Inspire Medical Systems, INC. | $522.33 | 2023-2025 | Inspire |
| Pfizer INC. | $465.44 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $390.66 | 2021-2025 | |
| Lilly USA, LLC | $360.21 | 2023-2025 | Amyvid, Emgality, Reyvow |
| Biogen, INC. | $309.63 | 2021-2025 | Tysabri, Vumerity |
| Eisai INC. | $268.05 | 2024-2025 | |
| Lundbeck LLC | $183.40 | 2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $168.25 | 2021-2025 | Ultomiris |
| Biohaven Pharmaceutical Holding Company LTD. | $163.83 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $145.47 | 2025 | Rexulti |
| Genentech USA, INC. | $115.99 | 2025 | Ocrevus Zunovo, Enspryng |
| Takeda Pharmaceuticals U.S.A., INC. | $109.92 | 2025 | Hyqvia |
| Acadia Pharmaceuticals INC | $97.01 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $95.29 | 2023 | Activa PC |
| Axsome Therapeutics, INC. | $91.34 | 2025 | Symbravo |
| Sk Life Science, INC. | $83.96 | 2025 | |
| Livanova USA, INC. | $81.36 | 2020-2021 | |
| Amgen INC. | $63.26 | 2025 | Uplizna |
| Harmony Biosciences LLC | $54.99 | 2025 | |
| Ge Healthcare | $54.39 | 2019-2025 | |
| Ucb, INC. | $31.76 | 2022 | |
| Novartis Pharmaceuticals Corporation | $24.65 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $23.86 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $22.98 | 2024 | Lumryz |
| Zoll Respicardia, INC. | $21.00 | 2025 | Remede System |
| Celgene Corporation | $16.45 | 2025 | Zeposia |
| Impel Pharmaceuticals LLC | $13.90 | 2025 | Trudhesa |
| Allergan, INC. | $12.20 | 2020 | |
| Vertical Pharmaceuticals, LLC | $12.05 | 2019 | |
| Bausch Health US, LLC | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bavis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.